J. Chiao

发表

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

L. Schwartz, H. Scher, P. Marks, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Chunlei Zhang, Madeleine Duvic, M. Duvic, 2007, Blood.

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

E. Raymond, S. Faivre, A. Gianella-Borradori, 2010, European journal of cancer.

Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer

M. Salto‐Tellez, B. Goh, R. Soong, 2009, Clinical Cancer Research.

RFC-1 Gene Expression Regulates Folate Absorption in Mouse Small Intestine*

F. Sirotnak, K. Roy, B. Tolner, 1997, The Journal of Biological Chemistry.

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Linda Z Sun, K. Anderson, C. Mitsiades, 2008, Leukemia & lymphoma.

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse.

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2009 .

A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2010 .

Histone deacetylase inhibitors: development as cancer therapy.

P. Marks, V. Richon, Thomas A. Miller, 2004, Novartis Foundation symposium.

Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)

E. Estey, J. Issa, H. Kantarjian, 2004 .

Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS).

E. Estey, J. Issa, H. Kantarjian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.

Jeffrey W. Clark, G. Shapiro, S. Rodig, 2016 .

Contrasting effects of oncogene expression on two carrier‐mediated systems internalizing folate compounds in Fisher rat 3T3 cells

F. Sirotnak, J. Chiao, J. Chiao, 2000, Journal of cellular physiology.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

L. Schwartz, H. Scher, P. Marks, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Changes in Lymphocyte Number and Phenotype in Seven Lymphoid Compartments After Thermal Injury

S. Calvano, J. Chiao, J. Chiao, 1989, Annals of surgery.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

V. Papadimitrakopoulou, M. Kies, J. Chiao, 2008, Investigational New Drugs.

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

L. Schwartz, L. Krug, T. Curley, 2006, Clinical lung cancer.

Phase I Clinical Trial of Histone Deacetylase Inhibitor : Suberoylanilide Hydroxamic Acid Administered Intravenously 1

L. Schwartz, H. Scher, P. Marks, 2003 .

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

C. Bowden, R. Nussenblatt, K. Cowan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in Free and Total Levels of Plasma Cortisol and Thyroxine Following Thermal Injury in Man

S. Calvano, G. Shires, J. Chiao, 1984 .

Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN).

A. Gillenwater, V. Papadimitrakopoulou, M. Kies, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

P. Venugopal, H. Kantarjian, T. Kadia, 2012 .

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2011 .

Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, T. Kadia, 2011, Journal of Clinical Oncology.

A Single Amino Acid Difference within the Folate Transporter Encoded by the Murine RFC-1 Gene Selectively Alters its Interaction with Folate Analogues

F. Sirotnak, B. Tolner, J. Chiao, 1998, The Journal of Biological Chemistry.

Ligand-directed Immunoaffinity Purification and Properties of the One-carbon, Reduced Folate Transporter

F. Sirotnak, K. Roy, J. Chiao, 1995, The Journal of Biological Chemistry.

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Linda Z Sun, D. Siegel, P. Richardson, 2007 .

279 POSTER Pharmacodynamic effects of seliciclib (r-roscovitine, cyc202) in patients with undifferentiated nasopharyngeal cancer (NPC) using a window trial design

M. Salto‐Tellez, B. Goh, R. Soong, 2006 .

Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design.

M. Salto‐Tellez, B. Goh, S. Green, 2005 .

Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer andBRCA1/2mutations

David R. Liu, E. Winer, G. Shapiro, 2019, Clinical Trials.

Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

G. Shapiro, D. Zheleva, D. Blake, 2018, Clinical Trials.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

G. Shapiro, D. Zheleva, D. Blake, 2020 .

Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .